Hester Biosciences Q1 FY27 Results

Standalone Revenue increased 14% year-on-year, while Standalone PAT surged 88% year-on-year. Standalone EBITDA grew 95% year-on-year.

Reader Takeaway: Strong domestic execution drives profit; international challenges persist.

What just happened

Hester Biosciences announced its quarterly financial results, showing a significant increase in standalone performance, particularly in Profit After Tax (PAT) and Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). The Poultry Healthcare division was a standout performer, growing 48% year-on-year. However, the company's consolidated revenue experienced an 8% decline compared to the previous year, attributed to challenges in its international markets, specifically Nepal and Africa.

Why this matters

The strong standalone results highlight the company's successful execution in its domestic market and operational efficiency improvements. The expansion in gross margins by 9 percentage points to 78% indicates better product mix and cost management. Conversely, the decline in consolidated revenue underscores the volatility and risks associated with international operations and dependency on government tenders in the animal healthcare sector.

The backstory

The company's Poultry Healthcare division has been a consistent growth driver. Recent strategic moves include the introduction of new products like feed supplements and disinfectants. International operations, particularly in Africa, have faced debt-related challenges. Hester Biosciences had a consolidated debt of Rs. 103 Crores as of June 30, 2026.

What changes now

Investors will be looking for Hester Biosciences to sustain its domestic growth momentum. The company has made progress in reducing debt in its African subsidiary, from USD 12 million to USD 5 million, with the outstanding amount now interest-free due to a waiver from the Gates Foundation. Capacity utilization across its manufacturing facilities, including new BSL3 and fill-and-finish plants, is around 60-65%.

Risks to watch

Continued revenue volatility in animal healthcare due to the timing of government immunization programs remains a risk. Stabilizing and improving revenue streams from international markets like Nepal and Africa is crucial. The company needs to manage receivables seasonally and ensure positive cash flow despite these external factors.

Peer comparison

(No direct peer comparison data available in the filing.)

Context metrics (time-bound)

• Standalone Revenue Growth: 14% YoY
• Standalone PAT Growth: 88% YoY
• Standalone EBITDA Growth: 95% YoY
• Poultry Healthcare Growth: 48% YoY
• Consolidated Revenue Growth: -8% YoY
• Gross Margin Expansion: +9 percentage points YoY
• African Subsidiary Debt Reduction: From USD 12 million to USD 5 million
• Manufacturing Capacity Utilization: 60-65%

What to track next

Investors should closely monitor the company's ability to improve its consolidated revenue performance, the sustained growth of the Poultry Healthcare division, and the successful management of international operations. The effective utilization of its expanded manufacturing capacity will also be key.